191 related articles for article (PubMed ID: 24111488)
1. Host defense peptides: general overview and an update on their activity against Chlamydia spp.
Di Francesco A; Favaroni A; Donati M
Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1215-24. PubMed ID: 24111488
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.
Wang SA; Papp JR; Stamm WE; Peeling RW; Martin DH; Holmes KK
J Infect Dis; 2005 Mar; 191(6):917-23. PubMed ID: 15717267
[TBL] [Abstract][Full Text] [Related]
3. Host defense peptides and their antimicrobial-immunomodulatory duality.
Steinstraesser L; Kraneburg U; Jacobsen F; Al-Benna S
Immunobiology; 2011 Mar; 216(3):322-33. PubMed ID: 20828865
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Chlamydial infections: 2014 update.
Kohlhoff SA; Hammerschlag MR
Expert Opin Pharmacother; 2015 Feb; 16(2):205-12. PubMed ID: 25579069
[TBL] [Abstract][Full Text] [Related]
5. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.
Brunham RC; Rey-Ladino J
Nat Rev Immunol; 2005 Feb; 5(2):149-61. PubMed ID: 15688042
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Chlamydia trachomatis Growth During the Last Decade: A Mini-Review.
Serradji N; Vu TH; Kim H; Panyam J; Verbeke P
Mini Rev Med Chem; 2018; 18(16):1363-1372. PubMed ID: 29692244
[TBL] [Abstract][Full Text] [Related]
7. Antibody-neutralizing activity against all urogenital Chlamydia trachomatis serovars in Chlamydia suis-infected pigs.
Donati M; Di Francesco A; Delucca F; Di Paolo M; Battilani M; Balboni A; Baldelli R; Cevenini R
FEMS Immunol Med Microbiol; 2011 Feb; 61(1):125-8. PubMed ID: 21214636
[TBL] [Abstract][Full Text] [Related]
8. [The importance of tetracycline treatment of cervical Chlamydia trachomatis infections: control with cervical smears].
Demirezen S; Ozcan M
Mikrobiyol Bul; 1988 Apr; 22(2):120-5. PubMed ID: 3273601
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of anti-Chlamydia trachomatis IgA antibody in the treatment of female genital tract chlamydial infections].
Kasamatsu T; Yokota H; Mizuno M; Kawana T
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Sep; 39(9):1649-50. PubMed ID: 3681060
[No Abstract] [Full Text] [Related]
10. Innate immunity in defense against Chlamydia trachomatis infections.
Severin JA; Ossewaarde JM
Drugs Today (Barc); 2006 Mar; 42 Suppl A():75-81. PubMed ID: 16683047
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of intracellular multiplication of human strains of Chlamydia trachomatis by nitric oxide.
Igietseme JU; Uriri IM; Chow M; Abe E; Rank RG
Biochem Biophys Res Commun; 1997 Mar; 232(3):595-601. PubMed ID: 9126319
[TBL] [Abstract][Full Text] [Related]
12. [Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].
Zele-Starcević L; Plecko V; Budimir A; Kalenić S
Acta Med Croatica; 2004; 58(4):329-33. PubMed ID: 15700690
[TBL] [Abstract][Full Text] [Related]
13. A cumulative experience examining the effect of natural and synthetic antimicrobial peptides vs. Chlamydia trachomatis.
Yasin B; Pang M; Wagar EA
J Pept Res; 2004 Aug; 64(2):65-71. PubMed ID: 15251032
[TBL] [Abstract][Full Text] [Related]
14. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection.
Su H; Morrison R; Messer R; Whitmire W; Hughes S; Caldwell HD
J Infect Dis; 1999 Oct; 180(4):1252-8. PubMed ID: 10479155
[TBL] [Abstract][Full Text] [Related]
15. Effects of sustained antibiotic bactericidal treatment on Chlamydia trachomatis-infected epithelial-like cells (HeLa) and monocyte-like cells (THP-1 and U-937).
Mpiga P; Ravaoarinoro M
Int J Antimicrob Agents; 2006 Apr; 27(4):316-24. PubMed ID: 16527461
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of the Chlamydia trachomatis species - immunopathology and infections.
Choroszy-Król IC; Frej-Mądrzak M; Jama-Kmiecik A; Bober T; Jolanta Sarowska J
Adv Clin Exp Med; 2012; 21(6):799-808. PubMed ID: 23457138
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Chlamydia trachomatis to protegrins and defensins.
Yasin B; Harwig SS; Lehrer RI; Wagar EA
Infect Immun; 1996 Mar; 64(3):709-13. PubMed ID: 8641770
[TBL] [Abstract][Full Text] [Related]
18. Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis.
Bowie WR; Lee CK; Alexander ER
J Infect Dis; 1978 Nov; 138(5):655-9. PubMed ID: 712119
[TBL] [Abstract][Full Text] [Related]
19. [Advances in the treatment of Chlamydia trachomatis infection].
Shi LL; Lu JC; Huangfu YM
Zhonghua Nan Ke Xue; 2005 Apr; 11(4):296-8. PubMed ID: 15921264
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo activity of roxithromycin against Chlamydia trachomatis.
Furneri PM; Sardo S; Cianci A; Palumbo G; Tempera G
J Chemother; 1991 Jan; 3 Suppl 1():36-8. PubMed ID: 12041782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
